Cambridge Cognition Holdings plc (AIM: COG), the neuroscience technology company, has announced the launch of Winterlight™ speech assessment tools to academic researchers through its CANTAB Connect Research platform. The move ends a previous restriction that limited Winterlight™ access to bespoke collaboration agreements, opening broader independent research opportunities. The launch also marks a milestone in the company's ongoing investment in speech-based biomarker technology, including an automatic speech recognition project initiated earlier in 2026. Investors may be watching the development as a potential driver of wider commercial adoption across pharmaceutical research and healthcare.

Key Points

  • Cambridge Cognition Holdings plc (AIM: COG) is a neuroscience technology company focused on digital cognitive assessments and biomarkers.
  • Winterlight™ speech assessment is now available to academic researchers via CANTAB Connect Research, previously accessible only through bespoke collaboration agreements.
  • CANTAB® technology underpins more than 3,700 peer-reviewed publications across 250-plus indications and has been used in over 600 clinical trials.
  • Investors should watch for evidence of expanded academic uptake translating into increased commercial demand in drug development and healthcare settings.

Winterlight™ Now Integrated Into CANTAB Connect Research for Multimodal Cognitive Studies

Researchers using the CANTAB Connect Research platform can now combine Winterlight™ speech tasks with the existing CANTAB® touchscreen assessments, questionnaires and scales within a single study. The company describes this as enabling complementary and multimodal measurement of cognitive performance. Until this launch, Winterlight™ was only accessible to academic researchers through individually negotiated collaboration agreements, meaning its availability was significantly more limited than the established CANTAB® toolset, which has been validated across more than 3,700 peer-reviewed publications and used in over 600 clinical trials globally.

Speech Biomarkers Capture Hundreds of Acoustic and Linguistic Measures From Brief Samples

The announcement highlights the scientific rationale behind speech as a cognitive assessment tool, noting that a short speech sample can generate hundreds of measures spanning acoustic and linguistic features including speech rate, pauses, vocabulary and sentence structure. The company states that this yields rich data with limited burden on participants. The announcement also references recent academic findings suggesting speech analysis has utility beyond neurology and psychiatry, including in detecting liver disease, underscoring the breadth of potential applications Cambridge Cognition is positioning Winterlight™ to serve across varied research settings.

Independent Academic Evidence Expected to Strengthen Winterlight™ Commercial and Clinical Adoption

Cambridge Cognition's CEO Rob Baker stated in the announcement that academic researchers play an important role in building independent evidence that supports wider adoption, and that the launch strengthens both the commercial opportunity for the speech offering and its longer-term value in pharmaceutical research and healthcare. The announcement also quotes Dr Sunny X Tang of the Feinstein Institutes for Medical Research, Northwell Health, citing a study of 266 participants in which a brief speech sample was sufficient to distinguish people with psychiatric disorders from healthy volunteers with good accuracy, adding to the evidence base for Winterlight™ clinical utility.

Automatic Speech Recognition Project Signals Continued Cambridge Cognition Investment in Speech Technology

The Winterlight™ academic launch coincides with what the company describes as the start of an automatic speech recognition project initiated earlier in 2026, presented in the announcement as part of Cambridge Cognition's continued investment in speech-based tools. The company states this will strengthen its leadership in the field and equip researchers, physicians and drug developers with richer insights. Built on more than 40 years of cognitive science, Cambridge Cognition combines CANTAB® assessments, Winterlight™ biomarkers, electronic clinical outcome assessments and data quality management within a scalable platform supporting clinic-based, hybrid and decentralised studies.